Skip to content
ESPT
MARKETS / NASDAQ / Health care / Diagnostics / MYGN
NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · MID CAP

Myriad Genetics Inc. MYGN

18 fiscal years on record · USD · FY2025 reported · SEC filings only
$824.5M
▼ 1.6% YoY
$-365.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Myriad Genetics designs tests that analyze genes and their expression levels to assess an individual's risk of developing disease, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression, identify factors that could lead to serious conditions in pregnancy, or provide other prenatal insights. As of December 31, 2025, it had approximately 2,700 full-time equivalent employees. Approximately 61% of its revenue comes from private third-party payors. It operates laboratories in West Salt Lake City, Utah and South San Francisco, California. The company focuses its efforts in three key areas: Oncology, Women's Health, and Mental Health. Its MyRisk test is a DNA sequencing test that determines a patient's hereditary cancer risk for breast, ovarian, uterine, renal, colorectal, endometrial, melanoma, pancreatic, prostate, skin, and gastric cancers. The company is a Delaware corporation with its principal executive offices located at 322 North 2200 West, Salt Lake City, Utah 84116.

Written from the business description in MYRIAD GENETICS INC's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 824.5M
Revenue, FY2025 · full 18-year series below
Revenue $M Net income $M
FY2025 · Revenue 824.5 · Net income -365.9
300M600M-150M-300M
2008201120142017202020232025
Compound annual growth
+6.7%
+8.2%
+1.1%
+4.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−44 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -47.0% · Net -44.4%
20%40%-20%-40%
200820162025
ROE
FY2025 · ROE -68.5%
10%20%30%-20%-40%-60%
200820162025
Three returns, three denominators.
Gross margin69.9%
Operating margin-47.0%
Net margin-44.4%
EBITDAUSD -367.7M

Each USD of equity lost 68 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -151.6
100M200M-100M-200M
200820162025
Net buybacks $M Dividends $M
FY2021 · Dividends · · Net buybacks 0.0
150M300M
200920112013201520182021
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 706.6M
EquityUSD 368.0M
CashUSD 149.6M
Gross debtUSD 119.9M
Net debtUSD -29.7M
Current ratio2.49×

The company holds more cash than debt.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
MYGN, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B0.80.80.80.70.70.60.60.90.70.70.70.70.80.60.50.40.40.3
Operating income $B−0.4−0.1−0.3−0.1−0.2−0.3−0.20.00.10.00.20.10.30.20.20.20.10.1
EBITDA $B−0.4−0.1−0.2−0.1−0.2◌−0.20.00.10.10.20.10.30.20.20.20.10.1
Income tax $B−0.00.00.0−0.0−0.0−0.1−0.0−0.0−0.00.00.00.10.10.10.10.1−0.00.0
Net income $B−0.4−0.1−0.3−0.1−0.0−0.2−0.20.00.10.00.10.10.20.10.10.10.20.1
Free cash flow $B◌◌◌−0.20.0◌0.10.10.10.10.20.10.20.20.10.10.10.1
EPS, diluted $−3.95−1.41−3.18−1.39−0.35−2.99−2.690.061.850.251.601.072.251.771.301.101.540.86
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————————————
ROE %−68.5−17.2−31.6−12.1−2.9−24.9−19.90.415.42.316.711.624.321.618.717.930.719.7
Shares out B0.090.090.090.080.080.080.070.070.070.070.070.070.070.080.080.090.09◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

Myriad Genetics Inc.vsIdexx Laboratories Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsQuidelOrtho Corp.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsLantheus Holdings, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsNeogen Corp.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsIntellia Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsCelldex Therapeutics, Inc.Same industry: In Vitro & In Vivo Diagnostic SubstancesMyriad Genetics Inc.vsTrinity Biotech PLCSame industry: In Vitro & In Vivo Diagnostic Substances
More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 75 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. One check was skipped: EPS is not tagged before 2008. One check was skipped: revenue is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image